New pill targets Hard-to-Treat KRAS cancers in first human trial
NCT ID NCT07458347
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This early-phase trial is testing an experimental oral drug called KST-6051 in adults with advanced or metastatic solid tumors that have a KRAS mutation, including certain lung, pancreatic, and colorectal cancers. The main goal is to check the drug's safety and how the body processes it. About 145 participants will take the pill by mouth, and researchers will also look for any signs that the drug is shrinking tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KST-6051 (an oral tablet)
What this could lead to
If this drug is safe and shows signs of shrinking tumors, it could point toward a new treatment option for people with KRAS-mutant cancers like lung, pancreatic, or colorectal cancer.
What could go wrong
This is a very early (Phase 1) trial focused on safety, not effectiveness. The drug may not work or could cause serious side effects. Only a small number of people will receive it at first.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cedars-Sinai Medical Center
RECRUITINGLos Angeles, California, 90048, United States
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
-
Huntsman Cancer Institute, University of Utah
RECRUITINGSalt Lake City, Utah, 84112, United States
-
Mass General Brigham Cancer Institute at Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
Sidney Kimmel Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States